Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the ...
As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent ...
AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...
Multiple myeloma and amyloidosis begin the same way – in plasma cells, white blood cells that help your immune system. But multiple myeloma (MM) is a rare blood cancer while amyloidosis is a buildup ...
CHICAGO — In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis. “Teclistamab has already been ...
AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...
In people with a rare condition called light chain amyloidosis, light chain proteins - which are a component of antibodies - mutate and build up in different organs. In new research published in The ...
CHICAGO — In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain ...
Neurofilament light chains in the serum and cerebrospinal fluid show strong potential for monitoring neurodegenerative and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback